The issue is not no matter whether retatrutide will work -- the data is powerful -- but how long the regulatory route normally takes and whether or not the approval lands with a safety profile that insurers and people can operate with.Artificial design: Although generally concentrating on GIP receptors, retatrutide is designed to also activate GLP-